TriangleTecartus (NCT06144606)
Tecartus trial for B-Cell Lymphoblastic Leukemia (NCT06144606). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with CD19-positive B-cell acute lymphoblastic leukemia in complete remission after induction treatment but still testing positive for minimal residual disease. Active leukemia in the brain or spinal coverings excludes participation.
The idea: use the patient's own modified T cells to recognize CD19 on leukemia cells. Patients receive conditioning chemotherapy, a rest day, then KTE-X19, also called Tecartus. Researchers measure how long remission lasts and assess safety. Some leukemia subtypes are excluded.
This phase 2 study plans 60 patients. Bijal Shah leads Moffitt's recruiting Tampa site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.